1207254-23-6 Usage
Uses
Used in Pharmaceutical Industry:
2-(HydroxyMethyl)hoMoMorpholine is used as a solvent for various pharmaceutical applications due to its ability to dissolve a wide range of organic compounds. Its strong polarity and low toxicity make it an ideal choice for dissolving active pharmaceutical ingredients and excipients in formulations.
Used in Agrochemical Industry:
In the agrochemical industry, 2-(HydroxyMethyl)hoMoMorpholine is utilized as a solvent for the formulation of pesticides and other agrochemical products. Its strong polar nature allows for the effective dissolution of active ingredients, enhancing the performance and efficacy of these products.
Used in Coatings Industry:
2-(HydroxyMethyl)hoMoMorpholine is employed as a solvent in the coatings industry to improve the solubility and performance of various types of coatings, such as paints, varnishes, and lacquers. Its strong polarity and miscibility with other solvents contribute to the improved flow, leveling, and drying properties of the coatings.
Used as a Solvent in Various Applications:
2-(HydroxyMethyl)hoMoMorpholine is used as a strong polar solvent for dissolving a wide range of organic compounds in various industries. Its low toxicity and low volatility make it a safer alternative to other solvents, reducing the potential for harmful environmental and health impacts.
Check Digit Verification of cas no
The CAS Registry Mumber 1207254-23-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,7,2,5 and 4 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1207254-23:
(9*1)+(8*2)+(7*0)+(6*7)+(5*2)+(4*5)+(3*4)+(2*2)+(1*3)=116
116 % 10 = 6
So 1207254-23-6 is a valid CAS Registry Number.
1207254-23-6Relevant articles and documents
Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors
Liu, Yifu,Xie, Zuoquan,Zhao, Dan,Zhu, Jin,Mao, Fei,Tang, Shuai,Xu, Hui,Luo, Cheng,Geng, Meiyu,Huang, Min,Li, Jian
, p. 2227 - 2244 (2017/04/03)
Pyruvate dehydrogenase kinases (PDKs) are overexpressed in most cancer cells and are responsible for aberrant glucose metabolism. We previously described bis(4-morpholinyl thiocarbonyl)-disulfide (JX06, 16) as the first covalent inhibitor of PDK1. Here, on the basis of the scaffold of 16, we identify two novel types of disulfide-based PDK1 inhibitors. The most potent analogue, 3a, effectively inhibits PDK1 both at the molecular (kinact/Ki = 4.17 × 103 M-1 s-1) and the cellular level (down to 0.1 μM). In contrast to 16, 3a is a potent and subtype-selective inhibitor of PDK1 with >40-fold selectivity for PDK2-4. 3a also significantly alters glucose metabolic pathways in A549 cells by decreasing ECAR and increasing ROS. Moreover, in the xenograft models, 3a shows significant antitumor activity with no negative effect to the mice weight. Collectively, these data demonstrate that 3a may be an excellent lead compound for the treatment of cancer as a first-generation subtype-selective and covalent PDK1 inhibitor.
NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS
-
Page/Page column 89, (2010/07/08)
The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.
